Welcome to your Sunday* Biotech & Pharma Stock Market Recap

(*I’m aiming for Saturdays but too busy moving this weekend!)

What’s to be covered in this hallowed scroll:

1. Overview of the biotech & pharma stocks that had the best & worst weeks (as measured by % change in price)

2. We’ll give you a calendar of whose announcing earnings in the upcoming week - and if they’re before the markets open (BMO) or after markets close (AMC).

3. One more thing we’ll have in future weeks - a recap of the more notable earnings calls the week previous.

Lastly - all three of the above will have sub-sections divided by:

1. Biotechnology (life sciences and the like)

2. Drug Manufacturers - General (this one includes big pharma)

3. Drug Manufacturers - Specialty and Pharma (everyone else that makes drugs, and then some)

And last thing - everything is in USD unless otherwise stated!

This weekend edition is a new feature at TLDR Biotech, so I’d love to get your feedback.

(You can also reach out to me on LinkedIn)

ENJOYING THESE NEWSLETTERS?
Consider an optional paid subscription.

TLDR Biotech is currently a one-person show that works full-time to put together these compilations and related content.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.

Biotechnology

Insmed had an Ins-ane week, and Summit Therapeutics shareholders are likely squealing with glee.

And though Verastem delivered the goods with positive interim Ph1/2 data, the safety data spooked investors.

(Some got so spooked that they’re alleging securities fraud.)

Upcoming Biotechnology Earnings Calls

Addex’s Ph2 flop didn’t entirely nullify it’s YTD performance - but remember that at one point this year, they were up over 300%.

Drug Manufacturers - General

Mira Pharmaceuticals YTD performance doesn’t look great, but it looks way worse if you look at only a month earlier (December 2023).

Upcoming Drug Manufacturers - General Earnings Calls

No earnings next week for this group! Instead, why not read about the biggest M&A deals in Pharma history?

Drug Manufacturers - Specialty & Generic

DURECT leads the growth again (last week they were up nearly 40%) likely riding the breakthrough wave, while Cardiol Therapeutics looks to be doing something right (or folks are just buying the rumor?).

In bad news, we have three repeat guests in the losers category, adding more losses to their May 20 - 24 performance below:

• Lucy Scientific Discovery (-40.41%)

• Sunshine BioPharma (-18.82%)

• Eagle Pharmaceuticals (-21.43%)

Upcoming Drug Manufacturers - Specialty & Generic Earnings Calls

No earnings next week for this group! Instead, why not check out this infographic on the biggest drug blockbusters of 2023 by revenue?

That’s all for now - go enjoy your weekend!

TLDR Biotech wants to hear from you! 📣 

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

And if you like this newsletter and think a friend or colleague would benefit, please share this with them! ♻️

Want to sponsor this newsletter and reach an audience of 100+ biotech and pharma professionals? Reach us here. 👍

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here